1-4 of 4
Jaya Sangodkar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation

Mario Scarpa, Prerna Singh, Christopher M. Bailey, Jonelle K. Lee, Shivani Kapoor, Rena G. Lapidus, Sandrine Niyongere, Jaya Sangodkar, Yin Wang, Danilo Perrotti, Goutham Narla, Maria R. Baer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 676–690.
https://doi.org/10.1158/1535-7163.MCT-20-0663
Published: 01 April 2021
View article titled, PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation
Open the PDF for PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation in another window
Includes: Supplementary data
Journal Articles

Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts

Fallon K. Noto, Valeriya Adjan-Steffey, Min Tong, Kameswaran Ravichandran, Wei Zhang, Angela Arey, Christopher B. McClain, Eric Ostertag, Sahar Mazhar, Jaya Sangodkar, Analisa DiFeo, Jack Crawford, Goutham Narla, Tseten Y. Jamling
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (11): 2481–2489.
https://doi.org/10.1158/1535-7163.MCT-18-0156
Published: 02 November 2018
View article titled, Sprague Dawley <em>Rag2</em>-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts
Open the PDF for Sprague Dawley <em>Rag2</em>-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts in another window
Includes: Supplementary data
Journal Articles

Abstract B124: Drugging the undruggable: development of small molecule activators of protein phosphatase 2A for cancer treatment

Jaya Sangodkar, Daniel McQuaid, Janna Kisselar, David Brautigan, Mark Chance, Michael Ohlmeyer, David Kastrinsky, Yiannis Ioannou, Goutham Narla
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B124.
https://doi.org/10.1158/1535-7163.TARG-15-B124
Published: 01 December 2015
View article titled, Abstract B124: Drugging the undruggable: development of small molecule activators of protein phosphatase 2A for cancer treatment
Journal Articles

Abstract A218: Simultaneous inhibition of both the PI3K-AKT and MAPK-ERK pathways using a single small molecule based approach for the treatment of advanced cancer.

Neil Dhawan, Blake Smith, Jaya Sangodkar, Vickram Gidwani, David Kastrinsky, Michael Ohlmeyer, Goutham Narla
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A218.
https://doi.org/10.1158/1535-7163.TARG-11-A218
Published: 12 November 2011
View article titled, Abstract A218: Simultaneous inhibition of both the PI3K-AKT and MAPK-ERK pathways using a single small molecule based approach for the treatment of advanced cancer.